Brainstorm Cell Therapeutics (BCLI) AI Stock Analysis

• Market Cap: $5.96M
• Dividend Yield: N/A
• Average Volume (3M): 22.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.08
• Revenue Growth: N/A
• EPS Growth: 58.09%
• Country: US
• Employees: 27
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.19
• Shares Outstanding: 11,034,775
• 10 Day Avg. Volume: 25,343
• 30 Day Avg. Volume: 22,935
• PEG Ratio: >-0.01
• Price to Book (P/B): -1.55
• Price to Sales (P/S): 14.20
• P/FCF Ratio: -1.33
• Enterprise Value/Market Cap: 1.58
• Enterprise Value/Revenue: 11.08
• Enterprise Value/Gross Profit: 16.19
• Enterprise Value/Ebitda: -0.88
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $0.58 ▲(0.34% Upside)

Overall score is held down mainly by weak financial performance (large operating losses, ongoing cash burn, and equity/funding risk). Technicals are also soft with the stock below key longer-term averages. Corporate events add some support via new financing and development progress, but carry dilution/financing risk, and valuation remains constrained by negative earnings and no dividend.

Positive Factors

Regulatory Advancements

Securing a special protocol assessment with the FDA reduces regulatory risks, enhancing the potential for successful approval and commercialization of NurOwn.

Strategic Partnerships

Collaborations with IQVIA and Pluri Inc. strengthen trial execution and production capabilities, supporting efficient development and potential market entry of NurOwn.

Cost Reduction Achievements

Significant cost reductions in R&D and administrative expenses improve financial efficiency, aiding long-term sustainability and resource allocation for strategic initiatives.

Negative Factors

Financial Constraints

Ongoing net losses and reduced cash reserves highlight financial challenges, potentially limiting operational flexibility and investment in growth initiatives.

Delays in Phase 3b Trial

Delays in the Phase 3b trial initiation could postpone potential market entry and revenue generation, impacting long-term growth prospects.

Skepticism About Efficacy

Skepticism about NurOwn's efficacy requires robust clinical data to gain market and investor confidence, crucial for successful commercialization.

Brainstorm Cell Therapeutics Business Overview & Revenue Model

Company Description

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

How the Company Makes Money

Brainstorm Cell Therapeutics generates revenue through the development and commercialization of its proprietary cellular therapies. The company's primary revenue stream is expected to come from the sale or licensing of NurOwn, pending regulatory approval and successful commercialization. Additionally, Brainstorm may engage in strategic partnerships and collaborations with pharmaceutical companies, research institutions, and other stakeholders to advance its clinical programs and expand its market reach. These partnerships may provide upfront payments, milestone payments, and royalties, contributing to the company's earnings. Other potential revenue sources include government grants and funding from non-profit organizations that support research in neurodegenerative diseases.

Brainstorm Cell Therapeutics Financial Statement Overview

Summary

Brainstorm Cell Therapeutics faces significant financial challenges, with ongoing losses and negative cash flows. Despite a slight improvement in equity, the company's financial stability is still at risk, requiring strategic changes to improve revenue and cash flow.

Income Statement

Brainstorm Cell Therapeutics shows a significant net loss for multiple years with minimal revenue in 2024. The gross profit margin is 100% due to its small revenue covering costs, but net profit margins remain negative. The revenue growth rate is not meaningful due to zero revenue in previous years. Continued negative EBIT and EBITDA margins indicate ongoing operational challenges.

Balance Sheet

The company has a fluctuating equity position, currently positive but previously negative. The debt-to-equity ratio is relatively low at 0.87, indicating some financial stability. However, the equity ratio is modest due to past negative equity, reflecting potential risk.

Cash Flow

Operating cash flow remains negative, indicating insufficient cash generation from operations. Free cash flow is also negative, with a significant growth in free cash flow loss compared to past years. The operating cash flow to net income ratio is not meaningful due to consistent net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	849.00K	849.00K	0.00	0.00	0.00	0.00
Gross Profit	581.00K	849.00K	-265.00K	-285.00K	-260.00K	-219.00K
EBITDA	-10.69M	-11.31M	-16.93M	-23.99M	-24.28M	-31.46M
Net Income	-10.85M	11.62M	-17.19M	-24.28M	-24.46M	-31.81M
Balance Sheet
Total Assets	872.00K	1.83M	4.21M	8.45M	29.28M	51.26M
Cash, Cash Equivalents and Short-Term Investments	5.00K	187.00K	1.30M	2.98M	22.09M	41.94M
Total Debt	326.00K	720.00K	1.27M	4.09M	5.08M	7.22M
Total Liabilities	50.00K	9.60M	9.07M	11.47M	9.94M	15.79M
Stockholders Equity	822.00K	-7.76M	-4.86M	-3.02M	19.34M	35.46M
Cash Flow
Free Cash Flow	-7.28M	-9.09M	-20.48M	-19.35M	-26.59M	-35.57M
Operating Cash Flow	-7.28M	-9.09M	-20.46M	-19.32M	-26.27M	-35.19M
Investing Cash Flow	12.00K	12.00K	2.19M	998.00K	323.00K	-4.45M
Financing Cash Flow	7.16M	7.97M	18.98M	238.00K	6.97M	76.94M

Brainstorm Cell Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.58
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCLI, the sentiment is Positive. The current price of 0.58 is above the 20-day moving average (MA) of 0.58, below the 50-day MA of 0.61, and below the 200-day MA of 0.84, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 49.24 is Neutral, neither overbought nor oversold. The STOCH value of 24.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BCLI.

Brainstorm Cell Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CYCN	47 Neutral	$6.48M	-2.25	-24.80%	―	1371.65%	64.13%
TCRT	45 Neutral	$7.03M	-1.23	-145.65%	―	―	68.59%
BCLI	44 Neutral	$5.96M	-0.40	―	―	―	58.09%
AIM	40 Underperform	$3.79M	-0.06	―	―	-41.05%	57.35%

Brainstorm Cell Therapeutics Corporate Events

Brainstorm Cell Therapeutics Secures New Convertible Debt Financing

On December 31, 2025, and January 5 and 6, 2026, Brainstorm Cell Therapeutics Inc. entered into three unsecured securities purchase transactions with institutional investors, issuing promissory and convertible promissory notes with original issue discounts and one-time interest charges, in aggregate principal amounts of $94,300, $94,875 and $140,000, respectively. The financings, which were conducted as private placements exempt from SEC registration, provided the company with short- to medium-term funding through discounted debt that may convert into equity at variable prices upon events of default or after specified holding periods, introducing potential future equity dilution while strengthening near-term liquidity and embedding investor protections such as default premiums, ownership caps, cross-defaults, and repayment rights tied to future financings.

The most recent analyst rating on (BCLI) stock is a Hold with a $0.58 price target. To see the full list of analyst forecasts on Brainstorm Cell Therapeutics stock, see the BCLI Stock Forecast page.

BrainStorm Cell Therapeutics Enters Securities Purchase Agreement

On November 10, 2025, BrainStorm Cell Therapeutics entered into a securities purchase agreement with Labrys Fund II, L.P., issuing a promissory note of $143,750 and receiving $121,500 after fees. The note is convertible into shares upon default, with specific payment terms leading to maturity on November 10, 2026. Additionally, BrainStorm announced its third-quarter financial results for 2025, highlighting a decrease in net loss compared to the previous year, and provided updates on its NurOwn Phase 3b clinical trial for ALS, which has received FDA clearance. The trial aims to enroll 200 participants and is designed to support a Biologics License Application. A Citizen Petition was filed with the FDA by the ALS community, underscoring interest in NurOwn’s potential.

The most recent analyst rating on (BCLI) stock is a Hold with a $6.60 price target. To see the full list of analyst forecasts on Brainstorm Cell Therapeutics stock, see the BCLI Stock Forecast page.

Brainstorm Cell Therapeutics Secures New Financing Agreement

On October 31, 2025, Brainstorm Cell Therapeutics entered into a securities purchase agreement with Vanquish Funding Group, issuing a promissory note for $182,400 and receiving $155,000 after fees. This agreement allows for potential additional financing of up to $2 million over the next year, impacting the company’s financial strategy and providing opportunities for further development.

The most recent analyst rating on (BCLI) stock is a Hold with a $6.60 price target. To see the full list of analyst forecasts on Brainstorm Cell Therapeutics stock, see the BCLI Stock Forecast page.